文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

台湾HIV感染者第二代整合酶抑制剂治疗失败后的耐药性分析

Resistance to second-generation integrase inhibitors in people with HIV following treatment failure on dolutegravir- or bictegravir-based ART in Taiwan.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

本研究为台湾多中心回顾性研究,纳入2016至2022年间在比克替拉韦或多替拉韦方案治疗失败且整合酶基因扩增成功的HIV感染者。第二代整合酶抑制剂耐药突变在比克替拉韦组检出率为5.5%(4/73),多替拉韦组为4.8%(6/127),两组间无显著差异(P=0.33)。常见突变为Q148H/K/R(3.5%)、G140A/C/R/S(3.0%)和R263K(1.5%),挽救治疗或继续使用第二代整合酶抑制剂方案可实现病毒抑制。

要点

  • 第二代整合酶抑制剂治疗失败时耐药突变总体检出率低,比克替拉韦组5.5%,多替拉韦组4.8%。
  • 常见耐药突变为Q148H/K/R、G140A/C/R/S和R263K,两组分布相当。
  • 挽救治疗或继续使用第二代整合酶抑制剂方案可使部分患者实现病毒再抑制。

核心结论

  • 第二代整合酶抑制剂治疗失败时耐药突变总体患病率低,比克替拉韦和多替拉韦方案相似。
  • 通过挽救治疗或继续使用第二代整合酶抑制剂方案可实现病毒再抑制。

研究设计与样本

  • 台湾多中心回顾性研究,纳入2016至2022年第二代整合酶抑制剂治疗失败且整合酶基因扩增成功的HIV感染者。
  • 比克替拉韦组73例,多替拉韦组127例,收集HIV-1亚型、血浆病毒载量、CD4计数和临床特征。
  • 使用2025 IAS-USA突变列表鉴定耐药突变,并用Stanford HIVdb算法解读。

主要发现

  • 失败时中位血浆病毒载量为4.7 log10 copies/mL,中位CD4计数为225 cells/mm3,组间无显著差异。
  • 第二代整合酶抑制剂耐药突变检出率:比克替拉韦组5.5%(4/73),多替拉韦组4.8%(6/127),P=0.33。
  • 常见耐药突变包括Q148H/K/R(3.5%)、G140A/C/R/S(3.0%)和R263K(1.5%),两组分布相当。
  • 8例保留在 care 的感染者中,4例换用挽救治疗后实现病毒抑制,4例继续使用基于整合酶抑制剂的方案。

关键数值与推荐

  • 耐药突变使用2025 IAS-USA突变列表鉴定,Stanford HIVdb算法解读。
  • 治疗失败定义为第二代整合酶抑制剂方案治疗失败且整合酶基因扩增成功。

临床怎么用

  • 对第二代整合酶抑制剂治疗失败的HIV感染者应进行基因型耐药检测以指导治疗决策。
  • 即使检出耐药突变,仍可考虑挽救治疗或继续使用第二代整合酶抑制剂方案以实现病毒再抑制。

局限性

  • 回顾性研究设计,样本量有限。
  • 仅纳入整合酶基因扩增成功的患者,可能存在选择偏倚。
  • 随访数据有限,仅8例有后续病毒抑制结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Resistance-associated mutations (RAMs) to second-generation integrase strand-transfer inhibitors (INSTIs) have been increasingly observed among people with HIV (PWH) who experienced virological failure on dolutegravir-based ART. However, data on dolutegravir resistance in the Asia-Pacific region remain limited, and data on RAMs during virological failure while receiving bictegravir-based ART are even more scarce. METHODS: In this multicentre, retrospective study in Taiwan, PWH with treatment failure on second-generation INSTI-based ART and successful amplification of the integrase gene were included. Data collected included HIV-1 subtypes, plasma viral loads (PVLs), CD4 counts and clinical characteristics. RAMs were identified using the 2025 IAS-USA mutation list and interpreted using the Stanford HIVdb algorithm. RESULTS: From 2016 to 2022, 73 and 127 PWH experienced treatment failure on bictegravir- and dolutegravir-based ART, respectively, and had successful genotypic resistance testing. Median PVL at failure was 4.7 log10 copies/mL, and median CD4 count was 225 cells/mm3, with no significant between-group differences. RAMs to second-generation INSTIs were detected in 5.5% (4/73) of bictegravir- and 4.8% (6/127) of dolutegravir-treated individuals (P = 0.33). Common RAMs included Q148H/K/R (3.5%), G140A/C/R/S (3.0%) and R263K (1.5%), with comparable distributions between the two groups. Among eight PWH retained in care, four achieved viral suppression after switching to salvage ART, and four with continuation of INSTI-based ART. CONCLUSIONS: Although RAMs to second-generation INSTIs may be detected during treatment failure, the overall prevalence remains low for both dolutegravir- and bictegravir-based ART. Viral resuppression can be achieved through salvage therapy or continued use of second-generation INSTI-based regimens.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Chen GJ, Lee NY, Tsai MS, et al. Resistance to second-generation integrase inhibitors in people with HIV following treatment failure on dolutegravir- or bictegravir-based ART in Taiwan. J Antimicrob Chemother. 2026. PMID: 41574657. doi:10.1093/jac/dkaf488

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。